Federal Policy

The federal government plays a key role in nearly every aspect of cancer policy – from funding research to determining what cancer screenings and treatments will be covered by Medicare, Medicaid and now, private insurers, through passage of the Affordable Care Act. Today more than ever, advocacy at the federal level matters. We have been actively engaged with Congress and key federal agencies to ensure that the needs of the lung cancer community are not forgotten.

Low dose CT screening for lung cancer is recommended by many professional societies for those at high risk. It is now an Essential Health Benefit and requires coverage from private insurance. Medicare has also recommended coverage for lung cancer screening. The final decision on that is pending.

Molecular testing is becoming more common in diagnosing and treating lung cancer. This is an important step to ensuring lung cancer patients get the treatments best for them. Read more about how we work to ensure coverage of molecular testing.